

June 22, 2015



## **AxoGen, Inc. to Present at the JMP Securities Life Sciences Conference**

**Nerve repair company AXGN to provide corporate update at investor conference.**

**ALACHUA, FL – June 22, 2015**– AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company dedicated to the \$1.6 billion peripheral nerve repair market, is scheduled to present at the JMP Securities Life Sciences Conference in New York on Wednesday, June 24, 2015 at 12:00 PM EST.

A live webcast and subsequent archived replay of the Company's presentation may be accessed via the Investor Relations section of the Company's website, <http://ir.axogeninc.com/>.

### **About AxoGen, Inc.**

AxoGen (NASDAQ: AXGN) is a leading medical technology company dedicated to peripheral nerve repair. AxoGen's portfolio of regenerative medicine products is available in the United States, Canada and several other countries and includes Avance<sup>®</sup> Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site, AxoGuard<sup>®</sup> Nerve Connector, a porcine submucosa extracellular matrix ("ECM") coaptation aid for tensionless repair of severed nerves, and AxoGuard<sup>®</sup> Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments.

Avance<sup>®</sup> Nerve Graft is processed in the United States by AxoGen. AxoGuard<sup>®</sup> Nerve Connector and AxoGuard<sup>®</sup> Nerve Protector are manufactured in the United States by Cook Biotech Incorporated, and are distributed worldwide exclusively by AxoGen. AxoGen maintains its corporate offices in Alachua, Florida and is the parent of its wholly owned operating subsidiary, AxoGen Corporation.

For more information about AxoGen or to sign up for our news alerts, please visit [www.AxoGenInc.com](http://www.AxoGenInc.com)

### **Cautionary Statement Concerning Forward-Looking Statements**

This Press Release contains "forward-looking" statements as defined in the Private Securities Litigation Reform Act of 1995, including statements about the closing of the over-allotment option and the AxoGen's proposed use of proceeds. These statements are based on management's current expectations or predictions of future conditions, events or results

based on various assumptions and management's estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as "expects", "anticipates", "intends", "plans", "believes", "seeks", "estimates", "projects", "forecasts", "continue", "may", "should", variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements may include, without limitation, statements regarding our growth, our product development, product potential, or the intended use of proceeds from the offering. The forward-looking statements are subject to risks and uncertainties, which may cause results to differ materially from those set forth in the statements. Forward-looking statements in this release should be evaluated together with the many uncertainties that affect AxoGen's business and its market, particularly those discussed in the risk factors and cautionary statements in AxoGen's filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those projected. The forward-looking statements are representative only as of the date they are made, and, except as required by law, AxoGen assumes no responsibility to update any forward-looking statements, whether as a result of new information, future events or otherwise.

**Contact:**

**AxoGen, Inc.**

Lee Robert "Bob" Johnston, Chief Financial Officer  
386.462.6856

[InvestorRelations@AxoGenInc.com](mailto:InvestorRelations@AxoGenInc.com)

**EVC Group**

Michael Polyviou / Doug Sherk – Investor Relations  
212.850.6020 / 415.652.9100

[mpolyviou@evcgroup.com](mailto:mpolyviou@evcgroup.com); [dsherk@evcgroup.com](mailto:dsherk@evcgroup.com)